Arthur G. Lipman, Pharm.D. - International Association for Hospice ...

More documents

Recommendations

Info

Arthur G. Lipman Page 24 Extramural Grants and Contracts - continued 1990-1991 Hoechst-Roussell Pharmaceuticals, Inc. Development of a data system for advanced cancer pain and its management, $5,000, Principal investigator. 1994 Syntex Laboratories Development of a continuing education program on pathophysiology and management of pain, $51,425 Principal investigator. 1996-1997 Vista Hospice Care Foundation Postdoctoral training program in pain and palliative care., $58,000 per year, Principal investigator. 1997-1099 VistaCare Foundation, Scottsdale Arizona Support for a Post Doctoral Fellowship in Pain and Palliative Care Pharmacy Research, $66,000 per year, Principal Investigator. 1998-1999 Alza Corporation Evaluation of E-TRANS (iontophoretic delivery) fentanyl for the treatment of breakthrough pain in conjunction with chronic pain, $22,000 Principle Investigator 1998-1999 Durect Corporation Study of subcutaneous sufentanyl in chronic pain management, $56,000, Principle Investigator 1998-1999 Robert Wood Johnson Foundation Utah partnership for improving care at the end of life planning grant, $75,000, Steering Committee member. 1999-2000 Purdue Pharma Physician Perceptions of the Role of Opioids in Chronic Nonmalignant Pain, Principle Investigator, $ 10,000 1999-2001 American Pain Society Development of clinical practice guidelines for pain management in arthritis, Co-Chair-Co Principle Investigator, $25,000 2000-2002 Robert Wood Johnson Foundation Utah partnership for improving care at the end of life implementation grant, $375,000, Steering Committee member 2001 Pharmacia Corp, Systematic Review Of Adverse Effects of Perioperative, Principle Investigator, $10,000 2001 Pharmacia Corp. Costs of adverse reactions to opioids in post surgical patients, Co-Investigator, $125,000 2001 American Pain Society Evidence Based Guidelines Program Systematic Review of the Effect of Pain and Opioids on Immune Response. Principle Investigator, $15,000 2001-2002 Janssen Pharmaceutica Outcomes study of controlled release opioids in low back pain , Co-investigator, 55,000. 2001-2002 Endo Pharamceuticals Dermal Lidocaine for Myofascial Pain, Principle Investigator, $26,000 2002-2007 NIH/NCI 2R01CA07424906A1 Pain and the Defense Response To study the effects of pharmacological manipulated noradrenergic arousal on the defense response. Sub investigator 2003-2004 Progenics Pharmaceuticals MNTX 301 A double-blind placebo-controlled study of methylnaltrexone (MNTX) for the relief of symptomatic constipation due to chronic opioid therapy in patients with advanced medical illness. Principal Investigator 2003-2004 Glaxo Smith Kline SB 767905-001 A randomized, double-blind, placebo-controlled, multicenter phase 3B study to evaluate the efficacy and safety of multiple alvimopan dosage regimens for the treatment of opioid-induced bowel dysfunction in subjects with chronic pain of non-malignant origin. Co-investigator continued
Arthur G. Lipman Page 25 Extramural Grants and Contracts - continued 2004-2005 Progenics Pharmaceuticals MNTX 302 A Double Blind Phase 3, Two-Week, Placebo Controlled Study of Methylnaltrexone (MNTX) for the Relief of Constipation Due to Opioid Therapy in Advanced Medical Illness Principal Investigator 2004-2005 UCB Pharma N02087 A double-blind, randomized, placebo-controlled parallel-group, 16 week, multicenter trial evaluating the efficacy and safety of levetiracetam 500 mg tablets in BID administration (daily dosing range from 1000 mg to 3000 mg ) in adults ( 18 years or age) suffering from postherpetic neuralgia. Principle Investigator 2006-2007 Medgenex, Inc A double-blind, randomized study of the efficacy of modafinil for the management of opioid-induced sedation Principle Investigator Intramural Grants and Contracts 1978-1981 University of Utah Research Committee A process study of clinical pharmacist activity in a university teaching hospital, $2,035, Principal Investigator. 1978-1981 Department of Health, Education and Welfare, Biomedical Research Support Grant Clinical Pharmacist Activity Outcome Study, Grant No. 507-RR-05738-07, $5,372, Principal Investigator. 1991-1992 University of Utah Research Committee Software development and implementation of a data system for advanced cancer pain and its management, $4,940, Principal Investigator. 2007-2008 University of Utah Interdisciplinary Seed Grant Drug Theory, Policy and Practice: An Interdisciplinary analysis $8,000, Principle Investigator
Page 1 and 2: Arthur G. Lipman Page 1 CURRICULUM
Page 3 and 4: Arthur G. Lipman Page 3 PUBLICATION
Page 5 and 6: Arthur G. Lipman Page 5 Chapters an
Page 7 and 8: Arthur G. Lipman Page 7 Articles in
Page 9 and 10: Arthur G. Lipman Page 9 Abstracts 1
Page 11 and 12: Arthur G. Lipman Page 11 Editorials
Page 17 and 18: Arthur G. Lipman Page 17 Drug Thera
Page 19 and 20: Arthur G. Lipman Page 19 Drug Thera
Page 21 and 22: Arthur G. Lipman Page 21 Book and M
Page 23: Arthur G. Lipman Page 23 GRANTS AND
Page 27 and 28: Arthur G. Lipman Page 27 EDITORIAL
Page 29 and 30: Arthur G. Lipman Page 29 Membership
Page 31 and 32: Arthur G. Lipman Page 31 University
Page 33 and 34: Arthur G. Lipman Page 33 CONTRIBUTE
Page 35 and 36: Arthur G. Lipman Page 35 INVITED PR
Page 43 and 44: Arthur G. Lipman Page 43 I*NVITED P
Page 57 and 58: Arthur G. Lipman Page 57 ] INVITED
Page 59: Arthur G. Lipman Page 59 COMMUNITY

Arthur G. Lipman, Pharm.D. - International Association for Hospice ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?